. Author manuscript; available in PMC: 2021 Apr 8.

Published in final edited form as: Aliment Pharmacol Ther. 2020 Apr 24;51(11):1031–1038. doi: 10.1111/apt.15719

Table 3.

Endpoints for Dual Biologic Therapy (DBT)

	Baseline	Post-Treatment

PRO-2 score (median) ^†	24.1	13.4
Clinical Remission	0/22 (0%)	9/22 (41%)
Mild	2/22 (9%)	2/22 (9%)
Moderate	20/22 (91%)	9/22 (41%)
Severe	0/22 (0%)	2/22 (9%)
Clinical Response	n/a	11/22 (50%)

Endoscopic ^‡
Remission	0/23 (0%)	6/23 (26%)
Improvement	n/a	10/23 (43%)

C-reactive protein (median)	17 mg/L	9 mg/L
Albumin (median)	36 g/L	37 g/L
Perianal fistula present	12/24 (50%)	8/24 (33%)
Required surgery	n/a	8/24 (33%)
Adverse event	n/a	3/24 (13%)
Serious adverse event	n/a	2/24 (8%)

^†

PRO-2 (Crohn’s disease-patient reported outcome-2 score) unable to be calculated in two trials due to presence of an ostomy.

^‡

Endoscopic endpoint data not yet available in four trials; three were consideredfailure of DBT due to surgery or entering a clinical trial - one was awaiting follow-up but achieved clinical response.